99 results
8-K
EX-99.1
ELOX
Eloxx Pharmaceuticals, Inc.
13 Nov 23
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
4:58pm
loss of $7.5 million, or $3.47 per share, which included $0.7 million in stock-based compensation.
R&D expenses were $1.3 million for the three months … ended September 30, 2023, which included $0.1 million in stock-based compensation. For the same period in the prior year, R&D expenses were $4.9
8-K
EX-99.1
ELOX
Eloxx Pharmaceuticals, Inc.
14 Aug 23
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
11:56am
a net loss of $10.6 million, or $4.90 per share, which included $0.7 million in stock-based compensation.
R&D expenses were $2.3 million for the three … months ended June 30, 2023, which included $0.3 million in stock-based compensation. For the same period in the prior year, R&D expenses were $7.7
8-K
EX-99.1
ELOX
Eloxx Pharmaceuticals, Inc.
15 May 23
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
6:01pm
of $11.6 million, or $5.36 per share, which included $0.9 million in stock-based compensation.
R&D expenses were $3.5 million for the three months ended … March 31, 2023, which included $0.3 million in stock-based compensation. For the same period in the prior year, R&D expenses were $7.9 million, which
8-K
EX-99.1
owtfcd4jsjw2wse
3 Apr 23
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
9:27am
8-K
EX-99.1
4oty pnnsb
14 Nov 22
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update
4:09pm
8-K
EX-99.1
3hojmgb yxk458z
15 Aug 22
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update
4:18pm
8-K
EX-99.1
8q290v avo7
10 May 22
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update
5:28pm
8-K
EX-99.1
nazrx8cpf39wp9o8 ew
4 Apr 22
Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update
8:45am
8-K
EX-99.2
san 1houf25ge9srv
17 Nov 21
Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
7:41am
8-K
EX-99.1
jivmdgu0cw90i4sxln4
9 Nov 21
Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update
8:03am